// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
A polygenic score for CAD identifies a top-percentile group with ~3× lifetime risk
Khera et al. Nat Genet 2018; replicated across UK Biobank, FinnGen, MVP.
Module 06 · Polygenic Risk & Early Warning →B
PRS adds incremental discrimination on top of pooled cohort equations / QRISK3
Modest C-statistic gain (~0.01–0.02) but meaningful net reclassification at intermediate-risk thresholds.
Module 06 · Polygenic Risk & Early Warning →F
European-trained PRS perform equally well in African-ancestry individuals
Documented R² loss of ~50% or more across most disease scores.
Module 06 · Polygenic Risk & Early Warning →B
PRS-guided breast-cancer screening start age improves cancer detection
BCSC + PRS modeling; pilot programs (CanRisk, MyPeBS) ongoing.
Module 06 · Polygenic Risk & Early Warning →E
Direct-to-consumer 'longevity PRS' tests give actionable individual guidance
Lifespan PRS R² is ~3–5%; individual guidance is overinterpretation.
Module 06 · Polygenic Risk & Early Warning →